Masato Ozaka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Masato Ozaka has a total of 535 co-authors. Here are the top co-authors by number of shared publications:
- Naoki Sasahira
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
37 shared publications - Takashi Sasaki
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
30 shared publications - Takafumi Mie
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
28 shared publications - Tsuyoshi Takeda
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan
27 shared publications - Akiyoshi Kasuga
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
26 shared publications - Takaaki Furukawa
Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
24 shared publications
Latest Publications
- Open Access
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8711
Comparison of Reintervention Outcomes After Endoscopic Ultrasound-Guided Hepaticogastrostomy According to the Type of Initial Stent
Background/Objectives: The impact of initial stent type on endoscopic reintervention after endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. Methods: We retrospectively evaluated patients with malignant biliary obstruction who developed recurrent biliary obstruction (RBO) after EUS-HGS and underwent reintervention through the endosonographically created route (ESCR). Outcomes were compared according to initial stent type (plastic stent [PS] or self-expandable metallic stent [SEMS]). The association between initial stent type and time to RBO (TRBO) after definitive biliary drainage was assessed using Cox regression and Fine–Gray regression. Results: Of 170 patients who underwent EUS-HGS, 69 were included (PS, n = 23; SEMS, n = 46). The initial reintervention procedure was technically successful in 100% and 95.7% of patients, respectively (p = 0.55). Definitive biliary drainage was technically successful in all 69 patients, while clinical success was achieved in 62 (89.9%). No procedure-related adverse events were observed. Among patients with clinical success, median TRBO was 160 and 140 days in the PS and SEMS groups, respectively. Initial SEMS placement was not significantly associated with TRBO (adjusted hazard ratio, 1.32; 95% confidence interval [CI], 0.55–3.13) or the cumulative incidence of RBO (adjusted subdistribution hazard ratio, 1.67; 95% CI, 0.70–3.97). Conclusions: Endoscopic reintervention through the ESCR was technically feasible after both initial PS and SEMS placement. Initial stent type was not significantly associated with subsequent RBO, although the findings should be interpreted cautiously because of potential temporal confounding and the limited sample size.
- 8 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8711
Open AccessComparison of Reintervention Outcomes After Endoscopic Ultrasound-Guided Hepaticogastrostomy According to the Type of Initial Stent
Background/Objectives: The impact of initial stent type on endoscopic reintervention after endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) remains unclear. Methods: We retrospectively evaluated patients with malignant biliary obstruction who developed recurrent biliary obstruction (RBO) after EUS-HGS and underwent reintervention through the endosonographically created route (ESCR). Outcomes were compared according to initial stent type (plastic stent [PS] or self-expandable metallic stent [SEMS]). The association between initial stent type and time to RBO (TRBO) after definitive biliary drainage was assessed using Cox regression and Fine–Gray regression. Results: Of 170 patients who underwent EUS-HGS, 69 were included (PS, n = 23; SEMS, n = 46). The initial reintervention procedure was technically successful in 100% and 95.7% of patients, respectively (p = 0.55). Definitive biliary drainage was technically successful in all 69 patients, while clinical success was achieved in 62 (89.9%). No procedure-related adverse events were observed. Among patients with clinical success, median TRBO was 160 and 140 days in the PS and SEMS groups, respectively. Initial SEMS placement was not significantly associated with TRBO (adjusted hazard ratio, 1.32; 95% confidence interval [CI], 0.55–3.13) or the cumulative incidence of RBO (adjusted subdistribution hazard ratio, 1.67; 95% CI, 0.70–3.97). Conclusions: Endoscopic reintervention through the ESCR was technically feasible after both initial PS and SEMS placement. Initial stent type was not significantly associated with subsequent RBO, although the findings should be interpreted cautiously because of potential temporal confounding and the limited sample size.
- Open Access
- 12 October 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
- 12 October 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Open AccessPembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial
- 19 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-12
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer
Background Gemcitabine plus nanoparticle albumin-bound-paclitaxel (GnP) therapy cause sometimes severe neutropenia in all the treatment period, which was reported to association with overall survival (OS). However, the relationship between pharmacokinetics-related genetic polymorphisms and both OS and early severe neutropenia in patients with metastatic pancreatic cancer receiving GnP therapy has not been adequately examined. We aimed to examine the associations between pharmacokinetic genetic polymorphisms involved in GnP, early severe neutropenia, and OS in Japanese patients with metastatic pancreatic cancer treated with GnP as first-line chemotherapy. Methods This multicenter prospective observational study enrolled 122 patients with metastatic pancreatic cancer who received GnP therapy. Twenty-two genetic polymorphisms related pharmacokinetics of GnP including ABCB1 were analyzed. Multivariable logistic regression and time-dependent Cox proportional hazards models were used to evaluate associations between these genotypes and early severe neutropenia up to day 14 and OS after applied inverse probability of treatment weighting. The significance level was set at 5%. Results Patients who developed early severe neutropenia had significantly longer median OS (523 vs. 249 days; adjusted hazard ratio [HR], 0.47; 95% confidence interval, 0.26–0.85; p = 0.012). The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC were significantly associated with severe neutropenia (adjusted odds ratio, 2.75; p = 0.020) and OS (adjusted HR, 0.56; p = 0.017). Conclusions Early-onset severe neutropenia could be associated with prolonged OS in patients with metastatic pancreatic cancer treated with GnP. The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC may help predict the risk of severe neutropenia and OS. Trial registration UMIN 000012720.
- 19 September 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-12
Association between ABCB1 genetic polymorphisms with treatment outcomes in patients with metastatic pancreatic cancer
Background Gemcitabine plus nanoparticle albumin-bound-paclitaxel (GnP) therapy cause sometimes severe neutropenia in all the treatment period, which was reported to association with overall survival (OS). However, the relationship between pharmacokinetics-related genetic polymorphisms and both OS and early severe neutropenia in patients with metastatic pancreatic cancer receiving GnP therapy has not been adequately examined. We aimed to examine the associations between pharmacokinetic genetic polymorphisms involved in GnP, early severe neutropenia, and OS in Japanese patients with metastatic pancreatic cancer treated with GnP as first-line chemotherapy. Methods This multicenter prospective observational study enrolled 122 patients with metastatic pancreatic cancer who received GnP therapy. Twenty-two genetic polymorphisms related pharmacokinetics of GnP including ABCB1 were analyzed. Multivariable logistic regression and time-dependent Cox proportional hazards models were used to evaluate associations between these genotypes and early severe neutropenia up to day 14 and OS after applied inverse probability of treatment weighting. The significance level was set at 5%. Results Patients who developed early severe neutropenia had significantly longer median OS (523 vs. 249 days; adjusted hazard ratio [HR], 0.47; 95% confidence interval, 0.26–0.85; p = 0.012). The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC were significantly associated with severe neutropenia (adjusted odds ratio, 2.75; p = 0.020) and OS (adjusted HR, 0.56; p = 0.017). Conclusions Early-onset severe neutropenia could be associated with prolonged OS in patients with metastatic pancreatic cancer treated with GnP. The combination of ABCB1 rs2032582 non-GG and rs1045642 non-CC may help predict the risk of severe neutropenia and OS. Trial registration UMIN 000012720.
- 28 August 2026
- Published by Springer Nature in Investigational New Drugs
- Vol. 44 (6) , 444-456
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
- 28 August 2026
- Published by Springer Nature in Investigational New Drugs
- Vol. 44 (6) , 444-456
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
- Open Access
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study
- 20 July 2026
- Published by Elsevier in ESMO Gastrointestinal Oncology
- Vol. 13
Open AccessNALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study
- Open Access
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Table 2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
HBV-related outcomes in evaluable participants with HBV infectiona.
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
HBV-related outcomes in evaluable participants with HBV infectiona.
- Open Access
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Purpose:In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the efficacy and safety of pembrolizumab plus chemotherapy.Patients and Methods:Eligible participants had histologically confirmed extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer, unresectable locally advanced or metastatic disease measurable per RECIST v1.1, known HBV and HCV status (including active HBV), and Eastern Cooperative Oncology Group performance status 0 or 1. Participants were randomly assigned 1:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks for ≤35 cycles plus gemcitabine and cisplatin. HBV-positive participants were monitored for HBV reactivation, and antiviral therapy was required for chronic HBV infection. The primary end point was OS.Results:The intention-to-treat population comprised 1,069 participants (533, pembrolizumab group; 536, placebo group). The median time from randomization to data cutoff (November 14, 2023) was 36.6 months (range, 29.2–49.4). Among 329 HBV-positive participants (30.8%), 30 had chronic and 299 had clinically resolved HBV. The OS HR was 0.87 [95% confidence interval (CI), 0.69–1.10] with pembrolizumab versus placebo for the HBV-positive subgroup and 0.85 (95% CI, 0.73–0.99) for the HBV-negative subgroup. Safety was consistent between the subgroups. Eight participants had HBV reactivation (5, pembrolizumab group; 3, placebo group), and no cases of HBV-associated hepatitis occurred in either group.Conclusions:Efficacy and safety outcomes were consistent between HBV-positive and HBV-negative participants receiving first-line pembrolizumab compared with placebo plus gemcitabine and cisplatin.Significance:Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Purpose:In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the efficacy and safety of pembrolizumab plus chemotherapy.Patients and Methods:Eligible participants had histologically confirmed extrahepatic or intrahepatic cholangiocarcinoma or gallbladder cancer, unresectable locally advanced or metastatic disease measurable per RECIST v1.1, known HBV and HCV status (including active HBV), and Eastern Cooperative Oncology Group performance status 0 or 1. Participants were randomly assigned 1:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks for ≤35 cycles plus gemcitabine and cisplatin. HBV-positive participants were monitored for HBV reactivation, and antiviral therapy was required for chronic HBV infection. The primary end point was OS.Results:The intention-to-treat population comprised 1,069 participants (533, pembrolizumab group; 536, placebo group). The median time from randomization to data cutoff (November 14, 2023) was 36.6 months (range, 29.2–49.4). Among 329 HBV-positive participants (30.8%), 30 had chronic and 299 had clinically resolved HBV. The OS HR was 0.87 [95% confidence interval (CI), 0.69–1.10] with pembrolizumab versus placebo for the HBV-positive subgroup and 0.85 (95% CI, 0.73–0.99) for the HBV-negative subgroup. Safety was consistent between the subgroups. Eight participants had HBV reactivation (5, pembrolizumab group; 3, placebo group), and no cases of HBV-associated hepatitis occurred in either group.Conclusions:Efficacy and safety outcomes were consistent between HBV-positive and HBV-negative participants receiving first-line pembrolizumab compared with placebo plus gemcitabine and cisplatin.Significance:Chronic HBV infection is a risk factor for BTC, potentially affecting the effectiveness of BTC treatment. In this study, treatment outcomes in participants who received first-line pembrolizumab plus gemcitabine and cisplatin for advanced BTC treatment were consistent regardless of HBV infection status.
- Open Access
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Summary of antiviral therapy in treated participants with HBV infection who received antiviral medication during the study
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Summary of antiviral therapy in treated participants with HBV infection who received antiviral medication during the study
- Open Access
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Representativeness of study participants.
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Representativeness of study participants.
- Open Access
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Baseline demographic and disease characteristics by chronic and clinically resolved HBV infection (ITT population)
- 17 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study
Baseline demographic and disease characteristics by chronic and clinically resolved HBV infection (ITT population)